← All stories
Markets
STAT+: Novartis’ experimental cardiovascular drug fails a pivotal study
A closely watched cardiovascular drug from Novartis failed in a pivotal study, the company said Friday, a major blow to the firm.
Covered by 1 outlet
All coverage · 1 article